Life Molecular patents expiration
1. Neuraceq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7907135 | LIFE MOLECULAR | Image display and image displaying method for gradation correction |
Mar, 2029
(4 years from now) | |
| US7807135 | LIFE MOLECULAR | Stilbene derivatives and their use for binding and imaging amyloid plaques |
Mar, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 21, 2019 |
Drugs and Companies using FLORBETABEN F-18 ingredient
NCE-1 date: 21 March, 2018
Market Authorisation Date: 19 March, 2014
Treatment: Neuraceq is a radioactive diagnostic agent for positron emission tomography (pet) imaging of the brain to estimate p-amyloid neuritic plaque density in adult patients with cognitive impairment
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
NEURACEQ family patents
